Medical castration using megestrol acetate and minidose estrogen. 1988

D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
Department of Urology, University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston.

Sixty-two men who presented with previously untreated metastatic carcinoma of the prostate (D0: 10 patients; D1: 29 patients; D2: 23 patients) received oral megestrol acetate (80 mg twice daily) and minidose estrogen (diethylstibestrol 0.1 mg or ethinyl estradiol 0.05 mg once daily) as a means of achieving total androgen ablation (testicular and adrenal). A high incidence of feminizing side effects (70-74%), a higher than expected rate of cardiovascular complications (18%), an unexpected need for cortisone replacement (13%), and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008535 Megestrol A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione,Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug

Related Publications

D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
April 1981, Urology,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
September 1988, Urology,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
March 1981, The Journal of clinical endocrinology and metabolism,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
April 1988, Seminars in oncology,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
October 1969, Zeitschrift fur Geburtshilfe und Gynakologie,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
September 1983, Cancer treatment reviews,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
December 1979, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
June 1989, Annals of internal medicine,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
April 1983, Cancer treatment reports,
D E Johnson, and R J Babaian, and D A Swanson, and A C von Eschenbach, and K I Wishnow, and D Tenney
January 1978, The Veterinary record,
Copied contents to your clipboard!